Brokerages Set CytomX Therapeutics, Inc. (NASDAQ:CTMX) PT at $5.02

CytomX Therapeutics, Inc. (NASDAQ:CTMX) has been assigned an average rating of “Moderate Buy” from the six analysts that are presently covering the firm, Marketbeat reports. Three equities research analysts have rated the stock with a hold rating and three have assigned a buy rating to the company. The average 1-year price objective among brokerages that have covered the stock in the last year is $5.02.

A number of equities analysts have recently issued reports on the stock. HC Wainwright reiterated a “neutral” rating on shares of CytomX Therapeutics in a research report on Friday, March 7th. StockNews.com lowered CytomX Therapeutics from a “buy” rating to a “hold” rating in a research report on Monday, March 31st. Finally, Wedbush restated an “outperform” rating and set a $5.00 target price on shares of CytomX Therapeutics in a research report on Friday, March 7th.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently made changes to their positions in the stock. Jacobs Levy Equity Management Inc. increased its holdings in CytomX Therapeutics by 1.1% in the third quarter. Jacobs Levy Equity Management Inc. now owns 1,524,076 shares of the biotechnology company’s stock valued at $1,798,000 after purchasing an additional 16,359 shares during the last quarter. Northern Trust Corp increased its stake in shares of CytomX Therapeutics by 16.0% in the 4th quarter. Northern Trust Corp now owns 150,632 shares of the biotechnology company’s stock valued at $155,000 after acquiring an additional 20,746 shares during the last quarter. Miller Financial Services LLC acquired a new stake in shares of CytomX Therapeutics in the 4th quarter valued at approximately $26,000. Connor Clark & Lunn Investment Management Ltd. boosted its stake in CytomX Therapeutics by 10.4% during the 3rd quarter. Connor Clark & Lunn Investment Management Ltd. now owns 280,593 shares of the biotechnology company’s stock worth $331,000 after acquiring an additional 26,373 shares during the last quarter. Finally, Prudential Financial Inc. grew its holdings in CytomX Therapeutics by 76.2% during the fourth quarter. Prudential Financial Inc. now owns 64,300 shares of the biotechnology company’s stock valued at $66,000 after purchasing an additional 27,800 shares during the period. 67.77% of the stock is currently owned by institutional investors.

CytomX Therapeutics Price Performance

CTMX stock opened at $0.46 on Friday. The business has a fifty day moving average price of $0.71 and a 200 day moving average price of $0.94. CytomX Therapeutics has a fifty-two week low of $0.45 and a fifty-two week high of $5.85. The stock has a market capitalization of $36.49 million, a price-to-earnings ratio of 2.68 and a beta of 1.33.

CytomX Therapeutics (NASDAQ:CTMX) last announced its earnings results on Thursday, March 6th. The biotechnology company reported $0.22 earnings per share for the quarter, beating analysts’ consensus estimates of ($0.23) by $0.45. The company had revenue of $38.09 million during the quarter, compared to analyst estimates of $13.53 million. CytomX Therapeutics had a negative return on equity of 41.47% and a net margin of 10.96%. On average, equities analysts expect that CytomX Therapeutics will post -0.05 earnings per share for the current fiscal year.

About CytomX Therapeutics

CytomX Therapeutics, Inc, an oncology-focused biopharmaceutical company, focuses on developing novel conditionally activated biologics localized to the tumor microenvironment. The company utilizes conditional activation platform technology for oncology biologics research and development comprising the validation of targets for antibody-drug conjugates (ADCs), opening therapeutic window for novel T-cell engagers (TCEs) targeting solid tumors, and increasing the therapeutic index for immune modulators, such as cytokines; and PROBODY platform in preclinical research in areas outside of oncology.